A small brain structure called the choroid plexus is already larger in people with optic neuritis and early MS, and it briefly grows more when new inflammation appears.
Researchers measured the size of the choroid plexus, a small tissue in the brain that helps make and filter cerebrospinal fluid (like a water filter for the brain), in three groups: people with optic neuritis as a first MS-like event, people with relapsing-remitting MS, and healthy volunteers. Both the optic neuritis group and the relapsing-remitting MS group had larger choroid plexus size than healthy people, meaning this change can be seen very early. Among the patients who later developed definite MS, choroid plexus size was similar to people with established MS and larger than healthy people. When new spots of inflammation showed up on brain MRI, the choroid plexus got temporarily bigger, like swelling during an infection, but then went back down. The choroid plexus size did not match how badly the optic nerve was inflamed, how much nerve damage there was later, or the total number of brain lesions, so it doesn’t seem to directly measure tissue damage.
People with optic neuritis and those who may be starting an MS journey should care because this change appears very early, helping doctors understand what’s happening in the brain even before big damage shows up. Caregivers and patients can think of the choroid plexus like a warning light that flickers with inflammation but doesn’t tell you how much damage has already happened. Neurologists and radiologists might use choroid plexus size as one more clue when looking at brain scans, similar to checking multiple signs in a car to diagnose a problem. This finding could help explain symptoms or guide closer monitoring after an initial optic neuritis event, for example scheduling follow-up scans. It may affect daily life by encouraging earlier check-ins with the care team after optic neuritis, but it does not yet change specific treatments on its own.
The study shows a link but not a cause — a larger choroid plexus doesn’t mean it causes MS or predicts how severe MS will be for one person. The increase in size was temporary with new inflammation and didn’t match measures of long-term nerve damage, so it’s not a clear marker of harm. More research is needed before using choroid plexus size to make medical decisions for individuals.
AI-generated summary — for informational purposes only, not medical advice
12/31/2026
Learn how certain gut bacteria can worsen MS symptoms and what this means for treatment and daily li
Read More5/1/2026
Study finds a brain‑seeking CD4 killer cell tied to MS and CMV exposure that may resist some treatme
Read More5/1/2026
Study shows after optic neuritis the ganglion cell layer (GCL) loses more tissue than the inner plex
Read More5/1/2026
Study finds CD29 marks blood B cells that can enter the brain and become antibody-producing cells in
Read More5/1/2026
Study finds specific spinal fluid proteins tied to early nerve damage in active MS, highlighting imm
Read More5/1/2026
Study finds early detection, lower spinal fluid virus, and PML‑IRIS relate to better 1‑year outcomes
Read MoreWhether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Multiple sclerosis (Houndmills, Basingstoke, England) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.